Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)
China · Delayed Price · Currency is CNY 7.52
-0.19 (-2.46%)
Sep 11, 2026, 3:00 PM CST
SHA:603229 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 778.08 | 792.26 | 795.07 | 814.85 | 764.23 | 568.89 |
Other Revenue | 0.43 | 0.5 | 0.22 | 1.92 | 0.32 | 0.81 |
| 778.5 | 792.76 | 795.29 | 816.77 | 764.55 | 569.7 | |
Revenue Growth | -0.80% | -0.32% | -2.63% | 6.83% | 34.20% | 39.21% |
Cost of Revenue | 399.03 | 388.15 | 373.39 | 372.41 | 372.58 | 261.29 |
Gross Profit | 379.48 | 404.61 | 421.9 | 444.36 | 391.96 | 308.41 |
Selling, General & Admin | 124.28 | 117.98 | 123.21 | 118.41 | 114.55 | 81.25 |
Research & Development | 169.43 | 167.89 | 100.42 | 78.06 | 67.07 | 68.82 |
Other Operating Expenses | 2.86 | 5.85 | 6.54 | 3.32 | 1.97 | 4.64 |
Operating Expenses | 287.5 | 287.41 | 237.43 | 199.81 | 186.76 | 156.21 |
Operating Income | 91.98 | 117.21 | 184.48 | 244.54 | 205.2 | 152.2 |
Interest Expense | -2.83 | -8.09 | -7.76 | -7.99 | -6.11 | -1.47 |
Interest & Investment Income | 32.26 | 46.16 | 43.08 | 35.75 | 9.6 | 5.78 |
Currency Exchange Gain (Loss) | -25.28 | -20.61 | 11.4 | 11.37 | 40.58 | -9.67 |
Other Non Operating Income (Expenses) | -45.64 | -0.29 | -0.27 | -0.6 | -0.44 | -0.44 |
EBT Excluding Unusual Items | 50.49 | 134.38 | 230.92 | 283.07 | 248.84 | 146.41 |
Gain (Loss) on Sale of Investments | 25.39 | -0.49 | 5.5 | -4.49 | 4.95 | 11.66 |
Gain (Loss) on Sale of Assets | 0.2 | - | - | - | - | -0.52 |
Asset Writedown | -3.67 | -1.48 | -0.15 | -0.37 | -1.58 | - |
Other Unusual Items | 1.11 | 5.5 | 3.93 | 12.55 | 3.66 | 1.84 |
Pretax Income | 73.52 | 137.9 | 240.2 | 290.76 | 255.86 | 159.39 |
Income Tax Expense | -7.54 | 7.33 | 33.41 | 36.86 | 20.48 | 13.46 |
Net Income | 81.06 | 130.57 | 206.79 | 253.9 | 235.38 | 145.93 |
Net Income to Common | 81.06 | 130.57 | 206.79 | 253.9 | 235.38 | 145.93 |
Net Income Growth | -58.70% | -36.86% | -18.55% | 7.87% | 61.29% | 68.05% |
Shares Outstanding (Basic) | 792 | 816 | 827 | 819 | 804 | 794 |
Shares Outstanding (Diluted) | 792 | 816 | 827 | 819 | 804 | 794 |
Shares Change | -5.90% | -1.34% | 0.99% | 1.92% | 1.16% | 6.67% |
EPS (Basic) | 0.10 | 0.16 | 0.25 | 0.31 | 0.29 | 0.18 |
EPS (Diluted) | 0.10 | 0.16 | 0.25 | 0.31 | 0.29 | 0.18 |
EPS Growth | -56.12% | -36.00% | -19.36% | 5.84% | 59.45% | 57.55% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -27.35 | 52.06 | 66.62 | 58.38 | -151.35 | -136.95 |
Free Cash Flow Per Share | -0.04 | 0.06 | 0.08 | 0.07 | -0.19 | -0.17 |
Dividend Per Share | 0.064 | 0.064 | 0.100 | 0.092 | 0.057 | 0.037 |
Dividend Growth | -36.00% | -36.00% | 8.58% | 61.30% | 53.91% | 62.72% |
Gross Margin | 48.74% | 51.04% | 53.05% | 54.40% | 51.27% | 54.14% |
Operating Margin | 11.82% | 14.79% | 23.20% | 29.94% | 26.84% | 26.72% |
Profit Margin | 10.41% | 16.47% | 26.00% | 31.09% | 30.79% | 25.61% |
Free Cash Flow Margin | -3.51% | 6.57% | 8.38% | 7.15% | -19.80% | -24.04% |
EBITDA | 172.31 | 190.06 | 248.13 | 285.14 | 239.68 | 182.22 |
EBITDA Margin | 22.13% | 23.97% | 31.20% | 34.91% | 31.35% | 31.99% |
D&A For EBITDA | 80.32 | 72.86 | 63.66 | 40.59 | 34.48 | 30.02 |
EBIT | 91.98 | 117.21 | 184.48 | 244.54 | 205.2 | 152.2 |
EBIT Margin | 11.82% | 14.79% | 23.20% | 29.94% | 26.84% | 26.71% |
Effective Tax Rate | - | 5.32% | 13.91% | 12.68% | 8.01% | 8.45% |
Revenue as Reported | 310.89 | 792.76 | 795.29 | 816.77 | 764.55 | 569.7 |